Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.55 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL957661 | 0.91 | ALKBH1 (0.47) | ALKBH1EPHB3SRD5A2NR4A2MEN1 | |
| SCHEMBL952858 | 0.89 | MEN1 (0.52) | ALKBH1EPHB3MEN1KMT2AMAOB | |
| SCHEMBL26670504 | 0.86 | PARP10 (0.43) | ALKBH1MAOBMAPK14 | |
| SCHEMBL954095 | 0.86 | ALKBH1 (0.42) | ALKBH1EPHB3SRD5A2MEN1KMT2A | |
| SCHEMBL26670510 | 0.85 | MEN1 (0.53) | ALKBH1EPHB3NR4A2MEN1KMT2A | |
| SCHEMBL26670516 | 0.85 | MAOB (0.44) | ALKBH1MAOBPOLB | |
| Hydrochloric Acid SCHEMBL958049 | 0.85 | ALKBH1 (0.42) | ALKBH1EPHB3SRD5A2MEN1KMT2A | |
| SCHEMBL16938261 | 0.81 | KDM4E (0.42) | — | |
| SCHEMBL18357700 | 0.80 | KDM4E (0.43) | EPHB3MEN1KMT2APOLB | |
| SCHEMBL26831008 | 0.80 | EPHB3 (0.42) | ALKBH1EPHB3MEN1KMT2ASCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376468-A1 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| CN-119998280-A | Pyrazolo [1,5-a ] pyridine derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-05-13 | — | — | CN | disclosed |
| EP-4499636-A2 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376468-A1 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM5, TRPM4 | ALKBH1 4636/4885EPHB3 1795/4885SRD5A2 3228/4885 |
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | ALKBH1 3052/4885EPHB3 4319/4885SRD5A2 916/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | ALKBH1 2560/4885EPHB3 2375/4885SRD5A2 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.